Catalyst Biosciences promotes Grant Blouse to CSO; CMO Howard Levy to retire Aug 15

GYRE THERAPEUTICS, INC.

Grant Blouse promoted to Chief Scientific Officer from SVP Translational Research; base salary $414,000 annually.
Blouse eligible for annual performance-based bonus up to 40% of base salary.
CMO Howard Levy to retire effective Aug 15, 2021; will join Clinical Advisory Board for hemophilia programs.
Levy's retirement not due to any disagreement with the company or its management.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Grant Blouse

Chief Scientific Officer

GYRE · GYRE THERAPEUTICS, INC.

Filed: July 15, 2021, 7:59 PM ET

On July 14, 2021, Catalyst Biosciences, Inc. (the “Company”) announced that Grant Blouse has been promoted to Chief Scientific Officer of the Company.

Departed

Howard Levy

Chief Medical Officer

GYRE · GYRE THERAPEUTICS, INC.

Effective: 2021-08-15
Filed: July 15, 2021, 7:59 PM ET

On July 14, 2021, the Company announced that Howard Levy, the Company’s Chief Medical Officer, plans to retire from his position.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Grant Blouse changed role as Chief Scientific Officer at GYRE THERAPEUTICS, INC..

Action: promoted
Role: Chief Scientific Officer

Exact text from the filing

On July 14, 2021, Catalyst Biosciences, Inc. (the “Company”) announced that Grant Blouse has been promoted to Chief Scientific Officer of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Howard Levy retired as Chief Medical Officer at GYRE THERAPEUTICS, INC..

Action: retired
Role: Chief Medical Officer

Exact text from the filing

On July 14, 2021, the Company announced that Howard Levy, the Company’s Chief Medical Officer, plans to retire from his position.

View on SEC.gov

GYRE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-21-216469

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.